{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:10:09Z","timestamp":1777597809538,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP18K06770"],"award-info":[{"award-number":["JP18K06770"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to evaluate the association between clinical characteristics and development of medication-related osteonecrosis of the jaw (MRONJ) in patients who underwent dental examinations before the initiation of treatment with denosumab or zoledronic acid, which are bone-modifying agents (BMAs), for bone metastases. Additionally, the clinical outcomes of patients who developed MRONJ were evaluated along with the time to resolution of MRONJ.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The medical charts of patients with cancer who received denosumab or zoledronic acid for bone metastases between January 2012 and September 2016 were retrospectively reviewed. Patients were excluded if they did not undergo a dental examination at baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 374 included patients, 34 (9.1%) developed MRONJ. The incidence of MRONJ was significantly higher in the denosumab group than in the zoledronic acid (27\/215 [12.6%] vs 7\/159 [4.4%], <jats:italic>P<\/jats:italic> = 0.006) group. Multivariate Cox proportional hazards regression analysis revealed that denosumab treatment, older age, and tooth extraction before and after starting BMA treatments were significantly associated with developing MRONJ. The time to resolution of MRONJ was significantly shorter for patients who received denosumab (median 26.8\u00a0months) than for those who received zoledronic acid (median not reached; <jats:italic>P<\/jats:italic> = 0.024).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results of this study suggest that treatment with denosumab, age &gt;\u200965\u00a0years, and tooth extraction before and after starting BMA treatments are significantly associated with developing MRONJ in patients undergoing treatment for bone metastases. However, MRONJ caused by denosumab resolves faster than that caused by zoledronic acid.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-021-06018-x","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T19:53:34Z","timestamp":1612209214000},"page":"4763-4772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8499-131X","authenticated-orcid":false,"given":"Hiroaki","family":"Ikesue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hirabatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Takenobu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsushi","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"6018_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"6018_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584","journal-title":"Ann Oncol"},{"key":"6018_CR3","doi-asserted-by":"crossref","unstructured":"Swain SM, Baselga J, Kim SB , Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cort\u00e9s J (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734","DOI":"10.1056\/NEJMoa1413513"},{"key":"6018_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SYS, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med 378:2078\u20132092","journal-title":"N Engl J Med"},{"key":"6018_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1634\/theoncologist.2007-0245","volume":"15","author":"M Aapro","year":"2010","unstructured":"Aapro M, Saad F, Costa L (2010) Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 15:1147\u20131158","journal-title":"Oncologist"},{"key":"6018_CR6","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00520-019-04676-6","volume":"27","author":"A Mjelstad","year":"2019","unstructured":"Mjelstad A, Zakariasson G, Valachis A (2019) Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration. Support Care Cancer 27:3859\u20133867","journal-title":"Support Care Cancer"},{"key":"6018_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, M\u00fcller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"6018_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"6018_CR9","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"6018_CR10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869\u20131876","journal-title":"Br J Cancer"},{"key":"6018_CR11","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A 95:3597\u20133602","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6018_CR12","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"6018_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"6018_CR14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"6018_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garc\u00eda-Sanz R, Durie B, Legie\u0107 W, Krej\u010d\u00ed M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19:370\u2013381","journal-title":"Lancet Oncol"},{"key":"6018_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"6018_CR17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"6018_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, al Dabagh R, Davison KS, Kendler DL, S\u00e1ndor GK, Josse RG, Bhandari M, el Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, on behalf of the International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"6018_CR19","doi-asserted-by":"crossref","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319","DOI":"10.1007\/s00774-016-0810-7"},{"key":"6018_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","volume":"125","author":"AA Owosho","year":"2018","unstructured":"Owosho AA, Liang STY, Sax AZ, Wu K, Yom SHK, Huryn JM, Estilo CL (2018) Medication-related osteonecrosis of the jaw: an update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 125:440\u2013445","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6018_CR21","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"6018_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A Badros","year":"2006","unstructured":"Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945\u2013952","journal-title":"J Clin Oncol"},{"key":"6018_CR23","doi-asserted-by":"publisher","unstructured":"Drudge-Coates L, Van den Wyngaert T, Schi\u00f8dt M, van Muilekom HAM, Demonty G, Otto S (2020) Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. Support Care Cancer 28:4019\u20134029. https:\/\/doi.org\/10.1007\/s00520-020-05440-x","DOI":"10.1007\/s00520-020-05440-x"},{"key":"6018_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"key":"6018_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99\u2013102","journal-title":"N Engl J Med"},{"key":"6018_CR26","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18:2015\u20132019","journal-title":"Ann Oncol"},{"key":"6018_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","volume":"139","author":"VM Cartsos","year":"2008","unstructured":"Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23\u201330","journal-title":"J Am Dent Assoc"},{"key":"6018_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","volume":"36","author":"MH Abu-Id","year":"2008","unstructured":"Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T (2008) \u201cBis-phossy jaws\u201d-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36:95\u2013103","journal-title":"J Craniomaxillofac Surg"},{"key":"6018_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jnci\/djm025","volume":"99","author":"GS Wilkinson","year":"2007","unstructured":"Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99:1016\u20131024","journal-title":"J Natl Cancer Inst"},{"key":"6018_CR30","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356\u20135362","journal-title":"J Clin Oncol"},{"key":"6018_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","volume":"125","author":"T Higuchi","year":"2018","unstructured":"Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A (2018) Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125:547\u2013551","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6018_CR32","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.joms.2016.12.014","volume":"75","author":"HY Kim","year":"2017","unstructured":"Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, Lee JH, Choung PH, Kim MJ, Seo BM (2017) Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. J Oral Maxillofac Surg 75:1404\u20131413","journal-title":"J Oral Maxillofac Surg"},{"key":"6018_CR33","doi-asserted-by":"crossref","unstructured":"Saad F, Brown JE, Van PC, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri\u00e8re P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","DOI":"10.1093\/annonc\/mdr435"},{"key":"6018_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3816\/CLM.2008.n.013","volume":"8","author":"AM Cafro","year":"2008","unstructured":"Cafro AM, Barbarano L, Nosari AM, D\u2019Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, D\u2019Avanzo G, Andriani A (2008) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 8:111\u2013116","journal-title":"Clin Lymphoma Myeloma"},{"key":"6018_CR35","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.clgc.2018.08.006","volume":"17","author":"A Guillot","year":"2019","unstructured":"Guillot A, Joly C, Barth\u00e9l\u00e9my P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K (2019) Denosumab toxicity when combined with anti-angiogenic therapies on patients with metastatic renal cell carcinoma: a GETUG study. Clin Genitourin Cancer 17:e38\u2013e43. https:\/\/doi.org\/10.1016\/j.clgc.2018.08.006","journal-title":"Clin Genitourin Cancer"},{"key":"6018_CR36","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00520-010-1061-0","volume":"19","author":"T Van den Wyngaert","year":"2011","unstructured":"Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB (2011) RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19:2035\u20132040","journal-title":"Support Care Cancer"},{"key":"6018_CR37","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00520-019-05044-0","volume":"28","author":"AL Soares","year":"2020","unstructured":"Soares AL, Simon S, Gebrim LH, Naz\u00e1rio ACP, Lazaretti-Castro M (2020) Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study. Support Care Cancer 28:2265\u20132271","journal-title":"Support Care Cancer"},{"key":"6018_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/0284186X.2016.1262548","volume":"56","author":"L Vehmanen","year":"2017","unstructured":"Vehmanen L, Suojanen J, Kontio R, Utriainen T, Blomqvist C (2017) High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. Acta Oncol 56:104\u2013106","journal-title":"Acta Oncol"},{"key":"6018_CR39","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/jbmr.2490","volume":"30","author":"RS de Molon","year":"2015","unstructured":"de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce RW, Dwyer D, Aghaloo TL, Tetradis S (2015) OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice. J Bone Miner Res 30:1627\u20131640","journal-title":"J Bone Miner Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06018-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06018-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06018-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T03:33:24Z","timestamp":1624851204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06018-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6018"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06018-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Kobe City Medical Center General Hospital. As this was a retrospective study, the research plan was published on the homepage of the hospital according to the instructions of the Ethics Committee in accordance with the guaranteed opt-out opportunity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"K Tomii has received a speaker honorarium from Daiichi Sankyo Co., Ltd., and Novartis Pharma K.K. H Yasi has received a research funding from Daiichi Sankyo Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}